Ex-Allergan CMO takes the helm at Lewis Cantley's metastasis-focused biotech startup
Allergan’s former top team is moving onto new adventures as AbbVie execs take direct control of their shop.
Just days after Brent Saunders pitched a $460 million SPAC for his next big move, his chief medical officer is taking up the CEO post at a biotech startup out of New York.
For Charles Hugh-Jones, the role at Volastra Therapeutics brings him back to a narrow focus on oncology, an area he’s specialized in throughout his years at Schering/Bayer, Sanofi, and eventually Pfizer. But instead of overseeing late-stage development, he is facing the challenge of bringing some early-stage drug candidates forward.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.